AT-752 is an orally administered direct-acting antiviral derived from Atea’s purine nucleotide prodrug platform and is being developed for the treatment of dengue fever. It works by impairing the dengue viral polymerase, which then inhibits replication of the virus. In preclinical studies, AT-752 showed potent in vitro activity against all dengue serotypes, as well as potent in vivo antiviral activity. These studies were conducted in small animal models. In a Phase 1 study, AT-752 was generally well tolerated.

Atea is conducting two clinical studies of AT-752. The first study is a Phase 2, global, randomized, double-blind, placebo-controlled trial in adult patients with dengue fever designed to evaluate the antiviral activity, safety and pharmacokinetics of multiple doses of AT-752 in areas where dengue is endemic. The second study is a human challenge study that is being conducted in the United States. The challenge study is designed to evaluate healthy subjects who are challenged with a Dengue Virus-1 Live Attenuated Virus strain after receiving AT-752 or placebo.